Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Weigel

Optometrist Olathe, KS Doctor of Optometry

NPI 1225220346 CMS profile 10023

11148 S Lone Elm Rd, Olathe, KS 66061

Open in the dashboard

General payments

$220,142

512 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Weigel of Olathe, KS is reported in the CMS Open Payments database as having received $220,142 across 512 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,517 43
2024 General $45,187 109
2023 General $10,971 36
2022 General $75,433 134
2021 General $26,826 55
2020 General $18,346 53
2019 General $26,861 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Weigel
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Justin Weigel were reported at $16,517. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Justin Weigel Optometrist median Middle half National median
2019 $26,861 $159 $67–$371 $163
2020 $18,346 $72 $29–$165 $114
2021 $26,826 $125 $46–$292 $132
2022 $75,433 $162 $66–$374 $149
2023 $10,971 $177 $72–$406 $160
2024 $45,187 $188 $77–$427 $164
2025 $16,517 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $146,971 308 payments
  2. Bausch & Lomb, a division of Bausch Health US, LLC $71,217 170 payments
  3. TissueTech, Inc. $351 7 payments
  4. Aerie Pharmaceuticals, Inc. $232 2 payments
  5. CooperVision Inc. $211 6 payments
  6. Alcon Vision LLC $205 5 payments
  7. Sight Sciences, Inc. $137 3 payments
  8. RxSight Inc $123 1 payment
  9. Oyster Point Pharma, Inc. $120 1 payment
  10. Dompe US, Inc. $113 1 payment
  11. Other $462 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $92,075 44 payments
  2. Travel and Lodging $50,171 181 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $32,400 24 payments
  4. Consulting Fee $19,700 20 payments
  5. Food and Beverage $13,308 232 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,488 11 payments
Products named General payments · program years 2019–2025
  1. INFUSE $86,751 199 payments
  2. BIOTRUE $43,231 87 payments
  3. EUREKA $39,242 63 payments
  4. ULTRA MULTIFOCAL TORIC $27,866 45 payments
  5. ULTRA $26,422 83 payments
  6. BIOTRUE ONE DAY $24,285 62 payments
  7. INFUSE MULTIFOCAL $7,663 13 payments
  8. ZEN LENS $3,945 6 payments
  9. BTOD $735 20 payments
  10. VYZULTA $289 1 payment
  11. Other $2,315 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

29

Median for Optometry: 120

Drug cost

$498

Median for Optometry: $8,864

Branded share of claims

0%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 29 $498

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$12,141

Medicare's payments for the services billed

Medicare patients

86

Average age 72

Services billed

193

43 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 41%
Depression 21%
Atrial fibrillation 20%
Cancer 20%
Chronic kidney disease 19%
Ischemic heart disease 17%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

512 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record